MX2012010429A - Dominio angiogenico sparc y metodos de uso. - Google Patents

Dominio angiogenico sparc y metodos de uso.

Info

Publication number
MX2012010429A
MX2012010429A MX2012010429A MX2012010429A MX2012010429A MX 2012010429 A MX2012010429 A MX 2012010429A MX 2012010429 A MX2012010429 A MX 2012010429A MX 2012010429 A MX2012010429 A MX 2012010429A MX 2012010429 A MX2012010429 A MX 2012010429A
Authority
MX
Mexico
Prior art keywords
methods
angiogenic domain
sparc
sparc angiogenic
domain
Prior art date
Application number
MX2012010429A
Other languages
English (en)
Inventor
Daniel Knauer
Neil Desai
Voung Trieu
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2012010429A publication Critical patent/MX2012010429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención proporciona composiciones y métodos los cuales explotan el descubrimiento del dominio angiogénico carboxi SPARC.
MX2012010429A 2010-03-11 2011-03-11 Dominio angiogenico sparc y metodos de uso. MX2012010429A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31304710P 2010-03-11 2010-03-11
US31305010P 2010-03-11 2010-03-11
PCT/US2011/028080 WO2011112921A2 (en) 2010-03-11 2011-03-11 Sparc angiogenic domain and methods of use

Publications (1)

Publication Number Publication Date
MX2012010429A true MX2012010429A (es) 2013-01-29

Family

ID=44564147

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010429A MX2012010429A (es) 2010-03-11 2011-03-11 Dominio angiogenico sparc y metodos de uso.

Country Status (10)

Country Link
US (1) US20130323263A1 (es)
EP (2) EP2630963A1 (es)
JP (1) JP2013522235A (es)
KR (1) KR20130010477A (es)
CN (1) CN102858362A (es)
AU (1) AU2011224154A1 (es)
CA (1) CA2792667A1 (es)
MX (1) MX2012010429A (es)
WO (1) WO2011112921A2 (es)
ZA (1) ZA201207455B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022084399A1 (en) * 2020-10-21 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) C-terminal sparc fragments for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5003621A (en) 1989-11-02 1991-03-26 Motorola, Inc. Direct conversion FM receiver
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
EP0950097A2 (en) * 1996-12-27 1999-10-20 Instituto de Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy
US20040018188A9 (en) * 1999-01-20 2004-01-29 Incyte Genomics, Inc. Sparc-related proteins
US6387664B1 (en) 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
BRPI0511126A (pt) * 2004-05-14 2007-11-27 Abraxis Bioscience Inc métodos de tratamento utilizando proteìnas de ligação de albumina como alvos
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
CA2655361C (en) * 2006-06-16 2014-10-07 Kumamoto University Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same
US8778302B2 (en) * 2007-03-09 2014-07-15 The University Of British Columbia Procaspase 8-mediated disease targeting
KR20130043242A (ko) * 2009-03-11 2013-04-29 아브락시스 바이오사이언스, 엘엘씨 Ｓｐａｒｃ 혈관형성 영역과 사용방법
AU2010253747B2 (en) * 2009-05-28 2013-07-11 Abraxis Bioscience, Llc Use of 2 anti-SPARC antibodies to predict response to chemotherapy

Also Published As

Publication number Publication date
EP2630963A1 (en) 2013-08-28
CN102858362A (zh) 2013-01-02
WO2011112921A3 (en) 2011-12-22
CA2792667A1 (en) 2011-09-15
WO2011112921A2 (en) 2011-09-15
EP2544704A4 (en) 2013-08-28
EP2544704A2 (en) 2013-01-16
JP2013522235A (ja) 2013-06-13
KR20130010477A (ko) 2013-01-28
US20130323263A1 (en) 2013-12-05
ZA201207455B (en) 2014-03-26
AU2011224154A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
PH12018500046A1 (en) Anti-mesothelin antibodies and immunoconjugates
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
IL222573A0 (en) Stabilized fibronectin domain compositions, methods and uses
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
AU333422S (en) Showerhead
MX2013007168A (es) Anticuerpo anti-pcsk9 y metodos de uso.
JO2860B1 (en) Phenylendazolyl compounds
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MY181898A (en) Heterocyclic compounds and uses thereof
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
IN2015DN00127A (es)
JO3755B1 (ar) تركيبات تستوستيرون
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
WO2010105097A8 (en) Sparc angiogenic domain and methods of use
IN2014DN00254A (es)
MX350392B (es) Aceite de sandalo y sus usos.
MX2010002950A (es) Metodos y composiciones para deteccion de ehrlichia chaffeensis (vlpt).
IN2014CN00312A (es)
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
MY165088A (en) Pharmaceutical compositions comprising alisporivir
IN2012DN01379A (es)
MX2012010429A (es) Dominio angiogenico sparc y metodos de uso.
UA41660U (en) Use of jacton and mexidol as actoprotector

Legal Events

Date Code Title Description
FA Abandonment or withdrawal